Both orthosteric and allosteric antagonists of the group II metabotropic glutamate receptors (mGlus) have been used to establish a link between mGlu2/3 inhibition and a variety of CNS diseases and disorders. Though these tools typically have good selectivity for mGlu2/3 versus the remaining six members of the mGlu family, compounds that are selective for only one of the individual group II mGlus have proved elusive. Herein we report on the discovery of a potent and highly selective mGlu2 negative allosteric modulator 58 (VU6001192) from a series of 4-oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides. The concept for the design of this series centered on morphing a quinoline series recently disclosed in the patent literature into a chemotype previously used for the preparation of muscarinic acetylcholine receptor subtype 1 positive allosteric modulators. Compound 58 exhibits a favorable profile and will be a useful tool for understanding the biological implications of selective inhibition of mGlu2 in the CNS.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817271PMC
http://dx.doi.org/10.1021/acs.jmedchem.5b01371DOI Listing

Publication Analysis

Top Keywords

negative allosteric
8
allosteric modulators
8
metabotropic glutamate
8
receptor subtype
8
design 4-oxo-1-aryl-14-dihydroquinoline-3-carboxamides
4
selective
4
4-oxo-1-aryl-14-dihydroquinoline-3-carboxamides selective
4
selective negative
4
allosteric
4
modulators metabotropic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!